Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 13 Sep 2018
Improving understanding of biosimilars in the EU
13 September 2018 - New information material made available in several European languages. ...
Posted by Michael Wonder on 06 Sep 2018
UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis
4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...
Posted by Michael Wonder on 03 Sep 2018
Biosimilar awareness initiative – literature review
3 September 2018 - The biosimilar literature review update for the period March 2018 to May 2018 is now available. ...
Posted by Michael Wonder on 22 Aug 2018
PBAC Drug Utilisation Sub-Committee utilisation analysis - public release documents
22 August 2018 - The utilisation analysis public release documents from the February 2018 DUSC meeting are now available. ...
Posted by Michael Wonder on 02 Aug 2018
NHS saved £324 million by switching to biosimilars and generics
2 August 2018 - The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar ...
Posted by Michael Wonder on 25 Jul 2018
A new cure, cheap for Hepatitis C is being ignored by thousands
23 July 2018 - Hepatitis C patient Jo Sloan was cured of the infectious disease, but her husband Les died ...
Posted by Michael Wonder on 24 Jul 2018
Prescribing biosimilars
24 July 2018 - Slow adoption is costly. ...
Posted by Michael Wonder on 23 Jul 2018
Precision medicine success hinges on diagnostics' clinical utility
23 July 2018 - The companion diagnostic plays a significant role in precision medicine. ...
Posted by Michael Wonder on 10 Jul 2018
Specialty drug coverage varies across commercial health plans in the US
9 July 2018 - Chambers et al. analysed specialty drug coverage decisions issued by the largest US commercial health plans ...
Posted by Michael Wonder on 02 Jul 2018
Is nudging biologic patients towards biosimilars a good choice for plan sponsors?
29 June 2018 - A recent study examining the potential savings determined that, based on the uptake of available biosimilars ...
Posted by Michael Wonder on 28 Jun 2018
High cost specialty drugs continue to dominate the new drug landscape
26 June 2018 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, ...
Posted by Michael Wonder on 20 Jun 2018
What's holding back market uptake of biosimilars?
20 June 2018 - Specialty biologics are currently the biggest driver of pharmaceutical cost growth. In the U.S., nine patents ...
Posted by Michael Wonder on 07 Jun 2018
Rapid rise in anti-HIV PrEP pills linked to drop in condom use
7 June 2018 - PrEP availability may play a part in men’s complacency about the chances of becoming infected, study suggests. ...
Posted by Michael Wonder on 22 May 2018
Janssen questions literature review on biosimilar switching studies as authors defend it
22 May 2018 - Three employees of Johnson & Johnson’s Janssen Pharmaceuticals, which has not publicly disclosed that it is ...